Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment
Authors:
- 10 August 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10867-10877
Abstract
No abstract availableKeywords
Funding Information
- College of Medicine, University of Arkansas for Medical Sciences (AWD55962)
This publication has 10 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and IndicationJAMA Health Forum, 2025
- Documentation of Compounded GLP ‐1 Receptor Agonists in a Large Primary Care DatasetPharmacoepidemiology and Drug Safety, 2025
- GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 20242025
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the USJAMA, 2025
- Socio‐demographic and clinical factors associated with the receipt of anti‐obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participantsDiabetes, Obesity and Metabolism, 2025
- Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatmentDiabetes, Obesity and Metabolism, 2025
- Factors Associated With Semaglutide Initiation Among Adults With ObesityJAMA Network Open, 2025
- Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fillsDiabetes, Obesity and Metabolism, 2024
- Using the Edmonton Obesity Staging System in the real world: a feasibility study based on cross-sectional dataCMAJ Open, 2021
- Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesityCanadian Medical Association Journal, 2011